<DOC>
	<DOCNO>NCT00645788</DOCNO>
	<brief_summary>To evaluate change forced expiratory volume ( FEV1 ) baseline Day 28-30 Cipro Inhale-treated placebo-treated subject 4-week treatment period .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Ciprofloxacin ( Inhaled ) Patients With Cystic Fibrosis</brief_title>
	<detailed_description>Safety issue address Adverse Events section .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Subjects , legal representative ( ) , must give write informed consent participate study receive adequate previous information prior study specific procedure Children ( 12 17 year ) adults &gt; /=18 year Documented diagnosis Cystic Fibrosis ( CF ) : document sweat chloride &gt; /=60 mEq/L quantitative pilocarpine iontophoresis test ( QPIT ) nasal potential difference either homozygous ΔF508 genetic mutation compound heterozygous 2 know CF mutation clinical finding consistent CF Chronic colonization P. aeruginosa define positive respiratory tract culture ( sputum throat swab ) within 12 month prior screen screen ( Note : subject negative culture screening , discretion investigator , rescreened later date ) Ability perform reproducible pulmonary function test Ability produce sputum ( noninduced ) Stable pulmonary status , FEV1 &gt; /=35 % &lt; /=75 % ( intraindividual variability +/10 % absolute value ) . Note : The subject eligible enrollment variability result ( lead ) FEV1 &lt; 35 % . Room air oximetry &gt; /=88 % saturation Off antibiotic ( except macrolide ) Cipro ( oral ) least 30 day prior administration study drug pulmonary exacerbation Stable regimen standard CF treatment include chest physiotherapy exercise regimen change 30 day prior administration study drug study ( include macrolide administration unchanged previous 30 day ) Subjects able understand follow instruction able participate study entire period Women willing use adequate method contraception 3 month receive study drug . Adequate method contraception include vasectomy condom use partner , diaphragm spermicidal gel , coil ( intrauterine device ) , surgical sterilization oral contraceptive Findings screen history physical examination unrelated CF could potentially affect efficacy measurement ( eg , chest surgery ) Subjects colonization Pseudomonas aeruginosa CIPRO MIC &gt; /=256 µg/ml mg/l Burkholderia cepacia complex colonization respiratory tract within past 12 month ( document screen laboratory ) Known aspergillosis ( unless asymptomatic ) . Patients invasive disease , ABPA IGE &gt; 500 mg/dL exclude Transaminase level &gt; 3x upper limit normal ( ULN ) Massive hemoptysis ( &gt; /=300 cc require blood transfusion ) precede 4 week Intravenous antibiotic treatment pulmonary exacerbation past 30 day Subjects medical disorder , condition history would impair subject 's ability participate complete study opinion investigator sponsor Febrile illness within 1 week start study Active treatment nontuberculosis mycobacteria Exposure investigational drug within 30 day Any history allergic reaction fluoroquinolones quinolones On oral steroid &gt; 20 mg/day longer 14 day past 3 month Creatinine &gt; /=2x ULN</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>sweat test</keyword>
	<keyword>pulmonary function test</keyword>
</DOC>